Dr. Xuefeng Yu, Chairman and CEO of China’s CanSino Biologics Inc., has underlined the importance of empowering local manufacturing companies in vaccine production as a crucial step toward meeting national healthcare needs.
During the World Local Production Forum 2025, Dr. Yu stressed that building strong partnerships with local firms is vital to boosting domestic manufacturing capabilities and ensuring high-quality vaccine output.
He applauded the UAE’s strategic commitment to becoming a regional biotechnology hub, calling it a forward-looking vision that positions the country at the forefront of health innovation.
Dr. Yu revealed that CanSino Biologics is actively collaborating with several UAE-based companies to expand local production in alignment with the nation’s growing healthcare demands. He highlighted that such efforts not only support public health resilience but also foster innovation and sustainability in the biotech sector.
Reflecting on past successes, Dr. Yu commended the robust UAE-China relationship, particularly in healthcare. He pointed to the COVID-19 pandemic as a pivotal moment of cooperation, noting the UAE’s key role in hosting clinical trials for Chinese-developed vaccines—an initiative that deepened bilateral trust and shared benefits.
Looking ahead, Dr. Yu expressed confidence in the continued strengthening of UAE-China collaboration. He emphasized that this evolving strategic partnership is well-positioned to deliver lasting advantages for both nations, especially in biotechnology and public health.
As the global focus shifts toward regional self-reliance in healthcare, Dr. Yu’s remarks reinforce the UAE’s growing stature as a biotech leader in the Middle East.
News Source: Emirates News Agency
